Curanex's Lead Drug Phyto-N Achieves Favorable Toxicology, Paving Way for IND Submission
CURX sits 51% above its 52-week low of $0.262.
Summary
Curanex Pharmaceuticals announced the successful completion of a 28-day repeat-dose toxicology study for its lead botanical drug candidate, Phyto-N. The study demonstrated a favorable toxicology profile with no significant adverse findings at the maximum feasible dose in both rats and dogs. This critical preclinical milestone significantly de-risks the program's safety profile and enables the company to advance to Good Laboratory Practice (GLP) toxicology studies. The positive results are a crucial step towards the planned Investigational New Drug (IND) application, which Curanex targets for submission in the fourth quarter of 2026. For a development-stage pharmaceutical company, this progress in its lead candidate is highly material and a key value driver. Investors should monitor the progress of the GLP studies and the eventual IND submission.
At the time of this announcement, CURX was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5M. The 52-week trading range was $0.26 to $9.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.